0000886163-19-000177.txt : 20190924 0000886163-19-000177.hdr.sgml : 20190924 20190924191101 ACCESSION NUMBER: 0000886163-19-000177 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190919 FILED AS OF DATE: 20190924 DATE AS OF CHANGE: 20190924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGGINS JOHN L CENTRAL INDEX KEY: 0001208906 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 191111767 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4/A 1 edgardoc.xml PRIMARY DOCUMENT X0306 4/A 2019-09-19 2019-09-23 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001208906 HIGGINS JOHN L 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 1 1 0 0 Chief Executive Officer 0.75% Convertible Senior Notes due 2023 248.48 2019-09-19 4 P 0 1175000 988468.75 A 2023-05-15 Common Stock 4729.0 1175000 D This amendment is being filed to correct the amount of securities purchased. The original Form 4 reported that the principal amount of 0.75% Convertible Senior Notes due 2023 was $1,000,000 with a purchase price of $841,250. The reporting person actually purchased $1,175,000 principal amount for a purchase price of $988,468.75 on the transaction date. The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. By: Charles S. Berkman For: John L. Higgins 2019-09-24